These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19271701)

  • 1. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.
    Akgün E; Körner M; Gao F; Harikumar KG; Waser B; Reubi JC; Portoghese PS; Miller LJ
    J Med Chem; 2009 Apr; 52(7):2138-47. PubMed ID: 19271701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea]: an irreversible cholecystokinin type-B receptor antagonist.
    Dunlop J; Brammer N; Evans N; Ennis C
    Biochem Pharmacol; 1997 Jul; 54(1):81-5. PubMed ID: 9296353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
    Hadac EM; Dawson ES; Darrow JW; Sugg EE; Lybrand TP; Miller LJ
    J Med Chem; 2006 Feb; 49(3):850-63. PubMed ID: 16451051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
    McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
    J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
    Harikumar KG; Cawston EE; Lam PCH; Patil A; Orry A; Henke BR; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Biol Chem; 2013 Jul; 288(29):21082-21095. PubMed ID: 23754289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCK receptor antagonists.
    Dunlop J
    Gen Pharmacol; 1998 Oct; 31(4):519-24. PubMed ID: 9792209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
    Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
    J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
    Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
    J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
    Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
    J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
    Chang RS; Lotti VJ
    Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
    Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
    Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
    J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
    Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
    Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.